We defined steroid treatment simply because prednisone or prednisolone therapy and excluded hydrocortisone for tension dosing. than various other autoAB+/LKM- topics. Steroid treatment of topics who had been autoAB+ had not been significantly connected with survival and the sub group with known diagnoses other than AIH had a higher risk of death. == Conclusions == AutoABs are common in children with ALF, occurring in 28%. AutoAB+ subjects have similar outcomes to autoAB unfavorable subjects. LKM+ children are more youthful and more likely to undergo liver transplantation compared to other autoAB+ subjects. Although AutoAB may show a treatable condition, positivity does not eliminate the need for a complete diagnostic evaluation as autoABs are present in other conditions. The significance of autoAB in PALF remains uncertain, but LKM+ appears to identify a unique population of children who merit further study. Keywords:pediatric liver transplant, autoantibodies, pediatric liver failure == Introduction == Acute liver failure (ALF) in children is usually a rare disease with multiple causes (1). Autoimmune hepatitis (AIH) is usually a cause of ALF, yet consensus in establishing diagnostic criteria for this condition in the presence of severe coagulopathy and encephalopathy has not been achieved(2-4). A classic combination of elevated IgG, characteristic autoantibodies (autoAB) [anti-smooth muscle mass antibody (SMA) or anti Doxazosin mesylate liver kidney microsomal antibody (LKM)], and a liver biopsy showing a plasmacytic infiltrate with either centrilobular or interface hepatitis leading to a consensus diagnosis of autoimmune hepatitis (AIH) and initiation of steroid therapy is usually infrequent in ALF(2,5). In adults with ALF, the presence of autoAB appears to be transient in many who have no other features characteristic of AIH (3,6,7). The significance of autoAB in the setting of ALF is usually unknown, and autoAB are often thought to be a non-specific response to antigens and not involved in the pathogenesis of liver injury (2). AutoAB are present in settings other than AIH. Antinuclear antibody (ANA) is present in 3-12% of healthy children although SMA and LKM are rarely found (8,9). AutoAB are present in well characterized chronic liver diseases in children such as chronic viral hepatitis (ANA 8-23%, SMA 1-18%, LKM 1-4%) (10,11) and main sclerosing cholangitis (ANA 43%, SMA 28%) (12) and in adults with non-alcoholic fatty liver disease (ANA Doxazosin mesylate 21%, SMA 5%) (13). AutoAB can also be present in acute or chronic presentations of Wilson disease (14). These autoAB are generally considered to represent epiphenomena and treatment is usually directed at the primary diagnosis rather than immunosuppression for AIH. It has been assumed that autoAB in children with ALF may arise similarly from non-specific liver injury. However, some children with ALF and positive autoABs have an acute presentation of AIH and respond to steroid therapy. To date, the frequency Doxazosin mesylate and significance of autoAB presence in PALF have not been investigated. The Pediatric Acute Liver Failure Study Group (PALFSG) is usually a NIH funded international consortium of pediatric centers that has been collecting Doxazosin mesylate data on children with ALF since 1999. Previous data from our group has shown that screening for autoAB is usually variable (15). The goals of this study are to describe the prevalence, associated clinical features and outcomes of the obtaining of positive autoAB in children in PALF using locally available assessments, supplemented by screening using a standardized central laboratory. == Methods == == PALF Study Group == Enrollment in the PALF study cohort began in December 1999. The PALF study protocol has been previously explained (1). IRB approval was secured at each of the clinical sites. Briefly, following informed consent, demographic, daily clinical, and laboratory information was recorded on case statement forms for up to 7 days following enrollment and end result was assessed up to 21 days or until death, liver transplantation, or hospital discharge without liver transplantation (survival with native liver) if occurring 21 days or less after enrollment (1). Diagnostic evaluation and medical management strategies were consistent with the standard of Rabbit Polyclonal to Cytochrome P450 26A1 care at each site and were not determined by the PALF protocol..